VOOPOO Wins "Ecigclick Best VAPE Brands" for Two Consecutive Years
On December 15, 2021, Ecigclick, the well-known vape review site in the UK, announced the results of Ecigclick Vape Awards 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005114/en/
Ecigclick Vape Awards 2021 (Graphic: Business Wire)
VOOPOO products won five awards including the Best Vape Brand 2021, becoming the benchmark brand winning the Best Vape Brand award for two consecutive years.
This outstanding annual achievement in awards, which covers different categories such as Mod, Pod Mod, Pod, Tank, once again verifies VOOPOO's excellent global brand influence. Its diversified product lineup has been recognized by the market and is well received by vapers worldwide.
The Ecigclick Vape Awards attracted more than 200 mainstream brands competing in various categories. More than 100,000 global vapers of mainstream communities from North America, the United Kingdom, and the European Union participated in the email voting.
This year, VOOPOO's four products (ARGUS, DRAG Nano 2, DRAG 3, TPP-X POD TANK) won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively, thanks to VOOPOO's consumer-based insight and diversified product strategy.
It is with the changes in the market environment and technological innovation that vapers are getting more demanding. Scenario-based, lightweight and diversified products are becoming more and more popular in the market.
In view of this, VOOPOO invested in new product series based on vaper value, and launched a product lineup integrating DRAG, VINCI, ARGUS, and V series to provide vapers with more suitable product solutions and to continue to enhance vaper experience.
Every vaper can find his favorite way to experience, no matter what he likes — Mod, Pod Mod or Pod. VOOPOO respects the vapers' own choice and is pleased to diversify its offering.
VOOPOO will continue to develop its product ecosystem, allowing its DRAG, VINCI, ARGUS, and V series to integrate with each other, so that consumers can enjoy a safe, reliable, and diverse product ecosystem that can meet diversified needs.
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown through DRAG products within a short period of time and is well recognized by vapers from around the world. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. Its business covers more than 70 countries and regions in North America, Europe and Asia. For more information, please visit our website and follow our IG, Facebook and TikTok.
About Ecigclick
Ecigclick is one of the vape sites with the widest coverage and most active vapers in the world. Ecigclick Vape Awards, as its annual voting event, has been successfully held for 9 years. Its forward-looking ranking is well recognized and has a deep influence in the industry.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005114/en/
Contact information
PR Manager: Wanfeng Chen
Media: wind.chen@voopoo.com
Business corporation: sales@voopoo.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new